Industry Symposia
Click on each title to see the details
GSK Symposium: Modifying the natural history of LN: from theory to clinical practice
Room America
Agenda:
10:30 – 10:45 Why consider Belimumab as SOC in LN? Disease modification concept – PROF ROGER A LEVY, GME GSK
10:45 – 11:00 From Concept to real world: Clinical Case Discussion (patient profile: LN) – PROF ANA MALVAR, ARG
11:00 – 11:15 What do the recommendations for Lupus Nephritis say? – PROF EDGARD TORRES, BRA
11:15 – 11:30 Q&A – ALL
Moderator: PROF ROGER LEVY, GME GSK (Brazil)
GSK Symposium: Herpes zoster and the rheumatic patient: Impact and prevention
Room Galapagos
Moderator: Jesse Reis Alves (Brazil), GSK Vaccines Medical Manager.
New approaches in the treatment of Psoriatic Arthritis
Room Oceania B
Agenda:
Unmet needs in the management of Psoriatic Arthritis – Dr Roberto Ranza
Risankizumab and Upadacitinib in the treatment of Psoriatic Arthritis – Dr Dennis McGonagle
Q&A – Dr Ranza & Dr McGonagle – all
Treatment target: long term and RWE data for remission and LDA with baricitinib in RA
Room Oceania A
Agenda:
- Lecture – Prof. Dr. Ricardo Blanco
- Q&A – Dr. Dawton Torigoe
Lecture will be in Spanish and local translation will be available.
10 years with infliximab biosimilar in rheumatic treatment: what is the next evolution?
Room Oceania B
Agenda:
16:15 – 16:25 Welcome Remarks – Dr. Salim Benkhalifa (France)
16:25 – 16:45 Biosimilarity and Beyond: Now and then of Infliximab – Dr. Valderilio Feijó Azevedo (Brazil)
10 years recap studies of infliximab biosimilar including pivotal and real-world studies.
16:45 – 17:05 Redefining Infliximab: the era of subcutaneous infliximab – Prof. Yannick Allanore (France)
Introduction of subcutaneous infliximab pivotal studies
17:05 – 17:15 Closing Remarks / Q&A – Dr. Salim Benkhalifa (France)
Moderator: Dr. Salim Benkhalifa (Francia)
Saphnelo® (anifrolumab) in SLE: thinking long-term for our patients
Room Oceania A
Agenda:
16:15 – 16:30 Welcome and introductions (Professor Odirlei Monticielo)
16:30 – 16:40 Balancing the benefits and risks of GCs in SLE (Professor Odirlei Monticielo)
16:40 – 16:55 Building the picture of treatment with Saphnelo – insights from long-term data (Doctor Grace Wright)
16:55 – 17:10 Striving for comprehensive control – a case in focus (Doctor Sheetal Desai)
17:10 – 17:15 Summary and close (Professor Odirlei Monticielo)
Spondylitis pain, are we really in control?
Room Galapagos
Agenda:
16:15 Welcome and introduction. Speaker
16:20 Spondylitis pain, are we really in control?. Speaker
17:10 Q&A. Speaker
Meet the Experts: Managing difficult SLE cases
Room Aruba
Agenda:
08:00 – 08:20 CLINICAL CASE I: +DISCUSSION
PROF LUCIANA SEGURO
PROF ROGER (MODERATOR)
08:20 – 09:00 CLINICAL CASE II +DISCUSSION
PROF MARINA SCOLNIK.
DRA ANA PATRICIA NASCIMENTO (MODERATOR)
What is the best therapeutic choice for my patient with PSA or axSpA?
Room America
Agenda:
- PSA discussion – Dr. Vinicius Domingues
- axSpA discussion – Prof. Xenofon Baraliakos
- Q&A – Dr. Rodrigo Luppino
Moderator: Dr. Rodrigo Luppino Assad (Brazil)
Upadacitinib in Rheumatoid Arthritis and its Role in Helping Patients Reach Treatment Goals
Room Oceania B
Agenda:
Unmet needs in RA management: Is there a treatment goal gap? – Dr Ricardo Xavier
Upadacitinib in the treatment of Rheumatoid Arthritis – Dr Eduardo Mysler
Q&A – Dr Xavier & Dr Mysler & all
